Sign up to access the white paper:
ICH E6(R3) is here, and places significant responsibility on sponsors to maintain quality across sample and biomarker data lifecycles. Both noncompliance and compliance have serious costs.
Disconnected sample and biomarker data workflows may be invisibly driving up costs of compliance, given that an average clinical trial can encounter tens of thousands of data issues, depending on the phase and complexity.
Request our white paper to see our breakdown of the costs associated with achieving and maintaining compliance using traditional processes and point solutions.
You’ll also learn how QuartzBio’s platform approach transforms compliance processes, helping customers lower costs immediately, reducing compliance issues and data problems by over 80%.
